MedTrace Logo

Continuous Versus Single-Shot Adductor Canal Block in Total Knee Arthroplasty

NCT03145584 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-05-09

No results posted yet for this study

Summary

Pain following total knee arthroplasty (TKA) is associated with delayed recovery, impaired mobility, increased morbidity, longer hospital stay and greater cost. Adductor canal block has recently been shown to improve the pain control of patients following TKA. It is not known whether a single shot technique or a continuous catheter-based infusion technique provides optimal analgesia. The investigators hypothesize that a continuous technique would provide better analgesia and permit patients to achieve objective measures of recovery following TKA than a single shot technique.

Conditions

  • Pain, Postoperative

Interventions

DRUG

Continuous Bupivacaine via Adductor Canal Saphenous Catheter

12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.

OTHER

Single Shot Adductor Canal Saphenous Block with Bupivacaine

A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation

Sponsors & Collaborators

  • University College Cork

    lead OTHER

Principal Investigators

  • Frank Loughnane, MB, FCARCSI · Cork University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-12-20
Completion
2015-12-31

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03145584 on ClinicalTrials.gov